Burbank, California 91505

  • Pulmonary Complications


RATIONALE: It is not yet known whether pleurodesis using a chest tube with infusions of talc is more effective in improving quality of life than pleurodesis using a small catheter in treating malignant pleural effusion. PURPOSE: Randomized phase III trial to compare the effectiveness of a chest tube and talc with that of a small catheter in treating malignant pleural effusion in patients who have cancer.

Study summary:

OBJECTIVES: - Compare the success rate in patients with cancer who undergo pleurodesis using a standard chest tube with talc slurry vs a small (PleurX) catheter for the treatment of a symptomatic unilateral malignant pleural effusion. - Compare the 30-day effusion control rate in patients treated with these procedures. - Compare quality of life in these patients at 7-14 and 30-37 days after treatment with these procedures. - Compare patient acceptance and satisfaction after treatment with these procedures. - Compare the level of symptoms and dyspnea experienced by patients treated with these procedures. - Compare the types, causes, and rates of early technical failures of these procedures in these patients. - Compare the 30-day effusion recurrences in patients treated with these procedures. - Compare the 60-day durability of pleurodesis in patients treated with these procedures. - Compare the mortality, morbidity, and common surgical complications in patients treated with these procedures. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to inpatient status (yes vs no), disease type (breast vs lung vs other), and concurrent systemic chemotherapy (yes vs no). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed. - Arm II: Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed. Quality of life and dyspnea are assessed at baseline and then at 7-14 and 30-37 days after treatment. Patients are followed at 30 and 60 days. PROJECTED ACCRUAL: A total of 530 patients (265 per treatment arm) will be accrued for this study within 3.5 years.


DISEASE CHARACTERISTICS: - Radiologic evidence of a unilateral malignant pleural effusion requiring sclerosis or ongoing drainage because it is symptomatic (dyspnea and/or progressive fatigue) - An asymptomatic patient is eligible if the patient underwent a prior thoracentesis within the past 2 weeks and was symptomatic before the procedure - No bilateral effusions by plain chest x-ray - Histologically or cytologically confirmed solid tumor or hematologic malignancy - Histologic confirmation of malignant cells in pleural fluid is not required - Pleural spaces must be naive to pleurodesis attempts - No prior intrapleural therapy (defined as a chest tube in place or placed to drain an effusion, prior surgical pleurectomy, or any prior chemical or mechanical pleurodesis on the ipsilateral side) - Placement of a small interventional radiology catheter for temporary drainage is not considered intrapleural therapy as long as no sclerosant medication was given and it has not been in place longer than 10 days PATIENT CHARACTERISTICS: Age - 18 and over Performance status - CTC 0-2 Life expectancy - Not specified Hematopoietic - Granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Not specified Renal - Not specified Pulmonary - No active pleural infection Other - No allergy to talc - No surgical contraindication to talc usage - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Concurrent systemic chemotherapy allowed Endocrine therapy - Not specified Radiotherapy - Concurrent palliative radiotherapy to a symptomatic lesion allowed except to the treated hemithorax within 30 days of the drainage procedure Surgery - See Disease Characteristics - Prior thoracotomies without specific pleural ablation (including lobectomy but not pneumonectomy) allowed - Prior needle-based diagnostic interventions (fine-needle aspiration, small bore catheter drainage of less than 10 days, or thoracentesis) allowed



Primary Contact:

Study Chair
Todd L. Demmy, MD
Roswell Park Cancer Institute

Backup Contact:


Location Contact:

Burbank, California 91505
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.